 | • レポートコード：MRC2302C146 • 出版社/出版日：360iResearch / 2023年2月3日 • レポート形態：英語、PDF、228ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に4,423.45百万ドルであった世界の遺伝子検査市場規模が、2022年に4,772.55百万ドルになり、2027年まで年平均8.06%で成長して7,046.44百万ドルに拡大すると予測しています。本レポートは、遺伝子検査の世界市場について調べ、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別（遺伝性がん検査、非遺伝性がん検査、新生児遺伝学的スクリーニング、非侵襲的出生前検査（NIPT）・キャリアスクリーニング、着床前遺伝子診断・スクリーニング）分析、技術別（生化学、細胞遺伝学、分子生物学的検査）分析、用途別（がん診断、循環器疾患診断、遺伝子疾患診断、その他）分析、エンドユーザー別（診療所、病院、その他）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。また、23andMe, Inc.、Abbott Laboratories、Agilent Technologies, Inc.、Beijing Genomics Institute、Bio-Helix Co. Ltd、Bio-Rad Laboratories, Inc.、Biocartis Group NVなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の遺伝子検査市場規模：疾患別 - 遺伝性がん検査の市場規模 - 非遺伝性がん検査の市場規模 - 新生児遺伝学的スクリーニングの市場規模 - 非侵襲的出生前検査（NIPT）・キャリアスクリーニングの市場規模 - 着床前遺伝子診断・スクリーニングの市場規模 ・世界の遺伝子検査市場規模：技術別 - 生化学における市場規模 - 細胞遺伝学における市場規模 - 分子生物学的検査における市場規模 ・世界の遺伝子検査市場規模：用途別 - がん診断用遺伝子検査の市場規模 - 循環器疾患診断用遺伝子検査の市場規模 - 遺伝子疾患診断用遺伝子検査の市場規模 - その他の市場規模 ・世界の遺伝子検査市場規模：エンドユーザー別 - 診療所における市場規模 - 病院における市場規模 - その他における市場規模 ・世界の遺伝子検査市場規模：地域別 - 南北アメリカの遺伝子検査市場規模 アメリカの遺伝子検査市場規模 カナダの遺伝子検査市場規模 ブラジルの遺伝子検査市場規模 … - アジア太平洋の遺伝子検査市場規模 日本の遺伝子検査市場規模 中国の遺伝子検査市場規模 インドの遺伝子検査市場規模 韓国の遺伝子検査市場規模 台湾の遺伝子検査市場規模 … - ヨーロッパ/中東/アフリカの遺伝子検査市場規模 イギリスの遺伝子検査市場規模 ドイツの遺伝子検査市場規模 フランスの遺伝子検査市場規模 ロシアの遺伝子検査市場規模 … - その他地域の遺伝子検査市場規模 ・競争状況 ・企業情報 |
The Global Hereditary Testing Market size was estimated at USD 4,423.45 million in 2021 and expected to reach USD 4,772.55 million in 2022, and is projected to grow at a CAGR 8.06% to reach USD 7,046.44 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Hereditary Testing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Disease Type, the market was studied across Hereditary Cancer Testing, Hereditary Non-cancer Testing, Newborn Genetic Screening, Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests, and Preimplantation Genetic Diagnosis & Screening. The Hereditary Cancer Testing is further studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Stomach/Gastric Cancer, and Uterine Cancer. The Hereditary Non-cancer Testing is further studied across Genetic Tests. The Genetic Tests is further studied across Cardiac Diseases, Other Diseases, and Rare Diseases.
Based on Technology, the market was studied across Biochemical, Cytogenetic, and Molecular Testing.
Based on Application, the market was studied across Cancer Diagnosis, Cardiovascular Disease Diagnosis, Genetic Disease Diagnosis, and Others.
Based on End-User, the market was studied across Clinics, Hospitals, and Others.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Hereditary Testing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hereditary Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Hereditary Testing Market, including 23andMe, Inc., Abbott Laboratories, Agilent Technologies, Inc., Beijing Genomics Institute, Bio-Helix Co. Ltd, Bio-Rad Laboratories, Inc., Biocartis Group NV, CENTOGENE N.V., CooperSurgical, Inc., CSL Ltd., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Fulgent Genetics, Inc., Igenomix, Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, Medgenome, Myriad Genetics, Inc, Natera Inc, Pacific Biosciences of California, Inc., Pathway Genomics Corporation, PerkinElmer, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, Sophia Genetics, Thermo Fisher Scientific, Inc., and Twist Bioscience.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Hereditary Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hereditary Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hereditary Testing Market?
4. What is the competitive strategic window for opportunities in the Global Hereditary Testing Market?
5. What are the technology trends and regulatory frameworks in the Global Hereditary Testing Market?
6. What is the market share of the leading vendors in the Global Hereditary Testing Market?
7. What modes and strategic moves are considered suitable for entering the Global Hereditary Testing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
5.1.1.2. Increased screening by pregnant women
5.1.2. Restraints
5.1.2.1. Limited reimbursement policies
5.1.3. Opportunities
5.1.3.1. Collaborative product development
5.1.3.2. R&D on advance Genome sequencing
5.1.3.3. Attractive investment and amalgamation activity within value chain
5.1.4. Challenges
5.1.4.1. Uncertain outcomes
5.2. Cumulative Impact of COVID-19
6. Hereditary Testing Market, by Disease Type
6.1. Introduction
6.2. Hereditary Cancer Testing
6.3.1. Breast Cancer
6.3.2. Cervical Cancer
6.3.3. Colorectal Cancer
6.3.4. Lung Cancer
6.3.5. Melanoma
6.3.6. Ovarian Cancer
6.3.7. Pancreatic Cancer
6.3.8. Prostate Cancer
6.3.9. Sarcoma
6.3.10. Stomach/Gastric Cancer
6.3.11. Uterine Cancer
6.3. Hereditary Non-cancer Testing
6.4.1. Genetic Tests
6.4.2.1. Cardiac Diseases
6.4.2.2. Other Diseases
6.4.2.3. Rare Diseases
6.4. Newborn Genetic Screening
6.5. Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
6.6. Preimplantation Genetic Diagnosis & Screening
7. Hereditary Testing Market, by Technology
7.1. Introduction
7.2. Biochemical
7.3. Cytogenetic
7.4. Molecular Testing
8. Hereditary Testing Market, by Application
8.1. Introduction
8.2. Cancer Diagnosis
8.3. Cardiovascular Disease Diagnosis
8.4. Genetic Disease Diagnosis
8.5. Others
9. Hereditary Testing Market, by End-User
9.1. Introduction
9.2. Clinics
9.3. Hospitals
9.4. Others
10. Americas Hereditary Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Hereditary Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Hereditary Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. 23andMe, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Abbott Laboratories
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Agilent Technologies, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Beijing Genomics Institute
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bio-Helix Co. Ltd
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bio-Rad Laboratories, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Biocartis Group NV
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. CENTOGENE N.V.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. CooperSurgical, Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. CSL Ltd.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Eurofins Scientific SE
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. F. Hoffmann-La Roche Ltd
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Fulgent Genetics, Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Igenomix
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Illumina, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Invitae Corporation
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Konica Minolta, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Laboratory Corporation of America Holdings
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Medgenome
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Myriad Genetics, Inc
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Natera Inc
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Pacific Biosciences of California, Inc.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Pathway Genomics Corporation
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. PerkinElmer, Inc.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Quest Diagnostics Incorporated
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. Siemens Healthineers AG
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
14.27. Sophia Genetics
14.27.1. Business Overview
14.27.2. Key Executives
14.27.3. Product & Services
14.28. Thermo Fisher Scientific, Inc.
14.28.1. Business Overview
14.28.2. Key Executives
14.28.3. Product & Services
14.29. Twist Bioscience
14.29.1. Business Overview
14.29.2. Key Executives
14.29.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing